Lisheng Pharmaceutical adjusts 2024 stock incentive plan

Tianjin Lisheng Pharmaceutical (SZSE:002393) has announced adjustments to its 2024 restricted stock incentive plan. The changes, approved by the board and shareholders, involve reducing the number of participants from 150 to 147 after three potential recipients voluntarily withdrew due to stock trading activities that occurred between being identified as possible recipients and the public disclosure of the incentive plan. The shares that would have been allocated to those three will be redistributed among the remaining participants. The total number of restricted shares to be granted remains unchanged at 7.21 million, which includes 5.77 million to be granted up front and 1.44 million to be reserved. Certain board members and high level management will receive a stake. The incentive plan aims to attract and retain key personnel. The changes are in compliance with relevant regulations and will not materially impact the company's financial situation.